Global Heart Hub’s Manifesto Published in PharmacoEconomics
Global Heart Hub’s Manifesto Published in the Electronic Journal of the IFCC
Read the article here: http://bit.ly/4pcSPUS
The economic case for early intervention in cardiovascular disease (CVD) prevention is clear. Early cardiovascular interventions have been found to be cost-effective from both healthcare and societal perspectives. Preventive strategies and timely diagnosis can reduce long-term healthcare costs and improve quality of life. “Investing in prevention, detection and diagnosis builds healthier populations, ensures the sustainability of healthcare systems, and creates positive impact across multiple sectors,” says lead author Prof Zanfina Ademi, Professor of Health Economics and Head of the Health Economics and Policy Evaluation Research Group at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia.
The article is based on Global Heart Hub’s patient-led manifesto, Achieving Early Detection and Diagnosis of Cardiovascular Disease: A Manifesto for Change, which was developed collaboratively by 125 international patient advocates, including 40 cardiovascular patient organisations and multidisciplinary expert opinion leaders. Equitable action in cardiovascular health is required, and Global Heart Hub’s Manifesto is centred around patients and carers with lived experience of CVD supported by global stakeholders. The Manifesto sets priority actions to improve CVD outcomes, calling for early detection and diagnosis of cardiovascular disease.
The article featured in PharmacoEconomics was authored by Zanfina Ademi, MPharm, MPH, PhD, Health Economics and Policy Evaluation Research, Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; Sheridan E. Rodda, B.Pharm (Hons), GradDip (HealthEcon), Health Economics and Policy Evaluation Research, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; Karl Vivoda, MPharm, Health Economics and Policy Evaluation Research, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; Susan Hennessy, PhD, University of California, San Francisco, United States of America; Olive Fenton, Global Heart Hub, Ireland; and James S Ware, PhD, National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK; Royal Brompton & Harefield Hospitals, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
